Employees
54
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Loading...
Open
15.15
Mkt cap
224M
Volume
923K
High
15.16
P/E Ratio
-168.28
52-wk high
15.89
Low
15.14
Div yield
1.00
52-wk low
11.53
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 8:36 pm
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 9:40 pm
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 9:34 pm
Portfolio Pulse from Benzinga Newsdesk
February 13, 2024 | 9:25 pm
Portfolio Pulse from Benzinga Newsdesk
February 13, 2024 | 9:24 pm
Portfolio Pulse from Benzinga Newsdesk
February 13, 2024 | 6:31 pm
Portfolio Pulse from Benzinga Newsdesk
November 02, 2023 | 9:45 pm
Portfolio Pulse from Benzinga Newsdesk
August 04, 2023 | 2:41 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.